NEUROGENE INC (NGNE)
US64135M1053 - Common Stock
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ: NGNE). Such investors...
Tuesday 11/26 Insider Buying Report: VTYX, NGNE
Top Buys by Top Brass: Chief Executive Officer McMinn's $969K Bet on NGNE
Top Buys by Directors: McMinn's $969K Bet on NGNE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ: NGNE). Such investors...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ: NGNE). Such investors...
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
Oversold Conditions For Neurogene (NGNE)
Neurogene — Down 36% — Extends Losses After Side Effect Derails Its Rett Syndrome Drug
The company is now scrapping a high dose of its Rett syndrome drug after a patient experienced a serious side effect.
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Notable Tuesday Option Activity: NGNE, VKTX, AVDL
Top 1% Biotech Neurogene Crashes, Wiping Out A Run, On A Serious Side Effect
Neurogene tested its gene therapy in female patients with Rett syndrome.
Neurogene Announces Oversubscribed $200 Million Private Placement
Noteworthy Wednesday Option Activity: WING, NGNE, VICR
Commit To Purchase Neurogene At $25, Earn 16% Using Options
NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024
NGNE stock results show that Neurogene missed analyst estimates for earnings per share the second quarter of 2024.
NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Neurogene (NASDAQ:NGNE) just reported results for the second quarter of 2024.Ne...
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
Neurogene to Participate in BMO Genetic Medicines Summit
